EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Thomas Powles, James W F Catto iD, Matthew D Galsky, Hikmat Al-Ahmadie iD, Joshua J Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G Kann iD, Tae-Hwan Kim und 14 weitere

New England Journal of Medicine · 14.11.2024 · 391 (19) · 1773-1786

DOI: 10.1056/nejmoa2408154 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 14.11.2024. Verfasst von Thomas Powles und 25 weiteren Autor:innen. Beteiligte Einrichtung: From Barts Cancer Institute, Queen Mary University of London, Barts Health NHS Trust Biomedical Research Centre, London (T.P.), the Division of Clini…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cystectomy, Deoxycytidine. Die Arbeit wurde bisher 459-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCystectomyDeoxycytidineUrinary Bladder NeoplasmsAntineoplastic Agents, ImmunologicalAdultAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantCisplatinGemcitabineKaplan-Meier EstimateNeoadjuvant TherapyProgression-Free SurvivalSurvival AnalysisAged, 80 and over

Substanzen

Antibodies, MonoclonalCisplatinDeoxycytidinedurvalumabGemcitabineAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • From Barts Cancer Institute, Queen Mary University of London, Barts Health NHS Trust Biomedical Research Centre, London (T.P.), the Division of Clinical Medicine, School of Medicine and Population Health, University of…

ORCID-Profile: James W F Catto, Hikmat Al-Ahmadie, Ariel G Kann

Förderung

  • AstraZeneca

Zitieren

APA

Powles, T., Catto, J. W. F., Galsky, M. D., Al-Ahmadie, H., Meeks, J. J., Nishiyama, H., Vu, T. Q., Antonuzzo, L., Wiechno, P., Atduev, V., Kann, A. G., Kim, T. H., Suárez, C., Chang, C. H., Roghmann, F., Özgüroğlu, M., Eigl, B. J., Oliveira, N., Buchler, T., …, & NIAGARA Investigators (2024). Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. New England Journal of Medicine, 391(19), 1773-1786. https://doi.org/10.1056/nejmoa2408154

Vancouver

Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. New England Journal of Medicine. 2024;391(19):1773-1786. doi:10.1056/nejmoa2408154

BibTeX
@article{Powles2024,
  author = {Powles, Thomas and Catto, James W F and Galsky, Matthew D and Al-Ahmadie, Hikmat and Meeks, Joshua J and Nishiyama, Hiroyuki and Vu, Toan Quang and Antonuzzo, Lorenzo and Wiechno, Pawel and Atduev, Vagif and Kann, Ariel G and Kim, Tae-Hwan and Suárez, Cristina and Chang, Chao-Hsiang and Roghmann, Florian and Özgüroğlu, Mustafa and Eigl, Bernhard J and Oliveira, Niara and Buchler, Tomas and Gadot, Moran and Zakharia, Yousef and Armstrong, Jon and Gupta, Ashok and Hois, Stephan and van der Heijden, Michiel S and NIAGARA Investigators, NIAGARA Investigators},
  title = {Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {19},
  pages = {1773--1786},
  doi = {10.1056/nejmoa2408154}
}
Kostenlos starten →